Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
Question
Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
Direct answer
Commercial adoption of RYONCIL generating $115.2 million in net product sales establishes base cash flow for MESO while Phase 3 back pain trial completion de-risks pipeline valuation. — bullish pressure on MESO via commercial cash flow expansion and clinical milestone completion.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-27
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial”, revision 1, evidence through 2026-08-27. https://marketontology.com/catalysts/2026-08-27/mesoblast-delivers-120-3m-fy26-revenue-and-concludes-phase-3-back-pain-trial-2df0d7
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| MESO | ▲Bull | 1–4 weeks | commercial cash flow expansion and clinical milestone completion | 59 |
Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
Commercial adoption of RYONCIL generating $115.2 million in net product sales establishes base cash flow for MESO while Phase 3 back pain trial completion de-risks pipeline valuation. — bullish pressure on MESO via commercial cash flow expansion and clinical milestone completion.
Reported $120.3M revenue with $115.2M from RYONCIL and completed Phase 3 treatment.
- SourceReported $120.3M revenue with $115.2M from RYONCIL and completed Phase 3 treatment.
- TransmissionCommercial adoption of RYONCIL generating $115.2 million in net product sales establishes base cash flow for MESO while Phase 3 back pain trial completion de-risks pipeline valuation.
- SummaryMesoblast achieved US$120.3 million in full-year FY26 revenue. RYONCIL commercial uptake accounted for US$115.2 million of total sales. Patient treatment has concluded in the Phase 3 rexlemestrocel-L chronic low back pain study.
- MESODirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- MESO closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- MESO price vs. pre-event level
- MESO volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Mesoblast Reports Substantial Revenue Growth to US$120M · polygon_news · 2026-08-27
Related catalysts
- 2026-08-27Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial LaunchMESO
- 2026-08-27Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial LaunchMESO
- 2026-08-27Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain TrialMESO
- 2026-08-27Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial LaunchMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for RyoncilMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for RyoncilMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for Ryoncil → Bullish MESOMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for Ryoncil → Bullish MESO → Bullish MESOMESO
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.